COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS

Tech ID: 32094 / UC Case 2021-004-0

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Published Application	20230285435	09/14/2023	2021-004

BRIEF DESCRIPTION

UC Berkley researchers have discovered compositions and methods for treating an RNA virus infection such as SARS-CoV-2 by administering an RNA-dependent RNA polymerase inhibitor, such as remdesivir, combined with a second FDA-approved therapeutic agent. Velpatasvir, Elbasvir, Dabrafenib, Omeprazole sulfide, Telmisartan, Selexipag, and Nifedipine are all FDA-approved molecules that have been shown to function synergistically with remdesivir for treating infection with an RNA virus.

SUGGESTED USES

» treatment of SARS-CoV-2 infections.

» It is also possible that combination therapy of remdesivir with a second therapeutic agent is efficacious in other viral diseases, such as Ebola, West Nile Virus, Hepatitis, Polio, Measles, Influenza, common cold, and others, and could be used for treatment of such commercially.

CONTACT

Terri Sale
terri.sale@berkeley.edu
tel: 510-643-4219.

INVENTORS

» Schaletzky, Julia Sabine

OTHER INFORMATION

CATEGORIZED AS

» **Medical**

» Disease: Infectious Diseases

» Therapeutics

RELATED CASES

2021-004-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

▶ Constructs, Plasmids And Specialized Reagents For E3 Ligase Project